Healing Actions of Essential Oils from Citrus aurantium and d-Limonene in the Gastric Mucosa: The Roles of VEGF, PCNA, and COX-2 in Cell Proliferation

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Cellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

The bias in reversing the Box-Cox transformation in time series forecasting: An empirical study based on neural networks

The Box-Cox transformation is a technique mostly utilized to turn the probabilistic distribution of a time series data into approximately normal. And this helps statistical and neural models to perform more accurate forecastings. However, it introduces a bias when the reversion of the transformation is conducted with the predicted data. The statistical methods to perform a bias-free reversion require, necessarily, the assumption of Gaussianity of the transformed data distribution, which is a rare event in real-world time series. So, the aim of this study was to provide an effective method of removing the bias when the reversion of the Box-Cox transformation is executed. Thus, the developed method is based on a focused time lagged feedforward neural network, which does not require any assumption about the transformed data distribution. Therefore, to evaluate the performance of the proposed method, numerical simulations were conducted and the Mean Absolute Percentage Error, the Theil Inequality Index and the Signal-to-Noise ratio of 20-step-ahead forecasts of 40 time series were compared, and the results obtained indicate that the proposed reversion method is valid and justifies new studies. (C) 2014 Elsevier B.V. All rights reserved.

Expressão da ciclooxigenase – 2 (COX-2) em carcinomas mamários espontâneos em cadelas

The immunohistochemistry regarding the expression of cyclooxygenase-2 (COX-2) for the woman’s breast cancer became a routine application due to the biological relevance. It is possible that COX-2 is closely related to tumor angiogenesis, inhibition of apoptosis mechanism, adhesion and metastasis. Herewith the COX-2 expression contributes to verify the malignant potential of the breast cancer. However it is slightly used in female dog’s spontaneous breast carcinomas. Keeping this in mind, the \cox-2 inhibitions appear as a promising perspective for the prevention and treatment of some sorts of cancer. The present dissertation had as main purpose to show the occurrence of the COX-2 expression in some of the female dog’s spontaneous breast carcinomas

Prostaglandina E2 em cães portadores de linfoma multicêntrico submetidos ao protocolo quimioterápico de Madison-Wisconsin associado ou não a um inibidor de COX-2

Pós-graduação em Medicina Veterinária - FCAV

Expressão gênica de MMP-2 e 9, TIMP-1 e 2, ATM, TP53, VEGF, COX-2 e CDH-1 no TVT canino

Pós-graduação em Medicina Veterinária - FCAV

Expressão gênica e proteica da cox-2 e c-Kit em neoplasias mamárias de cadelas

Pós-graduação em Medicina Veterinária - FCAV

Efeitos da inibição da cox-2 no sistema cardiovascular de cães

Os anti-inflamatórios não esteroidais (AINEs) estão entre os medicamentos mais prescritos em todo o mundo, tanto na medicina humana, como na medicina veterinária. Atualmente os AINEs são classificados em não seletivos (convencionais ou clássicos), que são os mais antigos, e seletivos para COX-2 ou coxibes. Alguns estudos constataram uma possível relação entre os inibidores COX-2 seletivos e os efeitos adversos no sistema cardiovascular. Devido a isso, objetivou-se realizar um levantamento de pesquisas que comprovem os efeitos cardiovasculares ocasionados por essa classe farmacológica utilizando livros e artigos das bases de dados PubMed, Periódicos da Capes e SciELO que respondessem à pergunta: a inibição da COX-2 acarreta efeitos adversos para o sistema cardiovascular?. Do total de resultados encontrados, foram utilizados 16 artigos. Os trabalhos mostraram que o uso de inibidores da COX-2 alterou o perfil de coagulação para uma tendência trombótica, além de diminuir a resposta vasodilatadora gerada na resposta inflamatória. Diante dos resultados obtidos através desses estudos, conclui-se que a COX-2 desempenha papel fisiológico no sistema cardiovascular, facilitando a não formação de trombos nos vasos sanguíneos, e, portanto, que sua inibição favorece a coagulação. Assim, os fármacos que inibem a COX-2 devem ser prescritos com cautela, levando-se em consideração o perfil de coagulação do paciente

Expressão imuno-histoquímica de KI-67, COX-2, MMP-9 e P53 nos tumores testiculares caninos

Pós-graduação em Ciência Animal - FMVA

Efeitos preventivos do treinamento físico na expressão das proteínas Cox-2 e Vegf de ratos tratados com dexametasona

Dexamethasone is a synthetic glucocorticoid widely used to treat allergic and inflammatory processes. This drug is used in three main situations, are used to contain acute or chronic inflammatory processes, or like immunosuppressive drug's. In these cases the patient will receive high doses for a chronic period and, therefore, has a much greater chance of adverse side effects, such as hypertension, diabetes and dyslipidemia. Dexamethasone promotes deleterious effects on the arachidonic acid pathway, when administered in high doses, because it is a potent anti-inflammatory drug. We recently demonstrated that dexamethasone significantly reduces the protein expression of vascular endothelial growth factor (VEGF) in both skeletal muscle and heart, but the mechanisms involved remain unclear. Meanwhile, exercise has been shown to be effective against high blood pressure, diabetes and dyslipidemia, promoting, among other factors, the increase in VEGF and angiogenesis. One possible explanation for these effects would be the creation of new vessels mediated by inflammation, or by the stimulation of the formation of products of the metabolism of arachidonic acid (AA), such as prostaglandin E2 (PGE2) and VEGF, by increasing the stimulation of the enzymes cyclooxygenase 1 and 2 (COX-1 and COX-2). Little is known about the preventive effects of training on the action of dexamethasone in the arachidonic acid pathway. Therefore, the aim of this study was to determine whether aerobic exercise training, performed before and concomitant treatment with dexamethasone, was able to prevent the effects of the dexamethasone in the protein expression of COX-2 and VEGF. For this, we used young Wistar rats (n = 40) which were randomly divided into 4 groups: sedentary control (SC), sedentary and treated with dexamethasone (SD), trained control (TC) and trained and treated with dexamethasone (TD). These rats performed aerobic exercise training, 60% of maximum capacity, 5

Efeitos preventivos do exercício físico sobre as proteínas ciclooxigenase-2 (COX-2) e fator de crescimento de vasos derivado do endotélio (VEGF) no músculo cardíaco em ratos tratados com dexametasona

Dexamethasone (DEXA) is a synthetic glucocorticoid widely used in the handling of several drugs, for its proven benefits in fighting inflammation and allergies. Despite their benefits, their chronic use leads to several side effects that include changes in the body in the metabolism of carbohydrates, lipids and proteins. Moreover, being an anti-inflammatory, acts on the arachidonic acid pathway, reducing the expression of the enzyme cyclooxygenase (COX-2) and growth factor derived from the endothelium of blood vessels (VEGF) in various tissues. However, its effects on the myocardium are still uncertain. The physical training (PT), in turn, promotes effects contrary to those caused by chronic use of DEXA, however, little is known about the preventive effects of TF in the side effects of Dexa in the myocardium. Therefore, the aim of this study was to determine if the TF has the ability to prevent and/or mitigate the effects of Dexa in protein expression of COX-2 and VEGF in the myocardium. Forty animals were divided into 4 groups: sedentary control (SC), sedentary treated with Dexa (SD), trained control (TC) and Trained treated with Dexa (TD) and submitted to a protocol of physical training on the treadmill for 70 days (1 h/day-5 days per week, 60% of physical capacity) or kept sedentary. Over the past 10 days, rats were treated with Dexa (Decadron, 0.5 mg/kg per day, ip) or saline. During training the animals were weighed weekly and during treatment daily. At the end of treatment was made to measure fasting glucose levels of animals. The rats were killed with excess anesthesia and cardiac muscle was removed, weighed, homogenized, centrifuged and stored at -20° C for analysis of protein expression of VEGF and COX-2 by Western blotting technique. Treatment with dexamethasone caused a weight loss of 18% in sedentary animals and 13% in trained as well as elevated levels of fasting glucose in sedentary (88%). The TF was unable to mitigate the loss in...